View Older Stories View More Recent Stories

Oct 17, 2017 08:30AM Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics
Oct 16, 2017 08:00AM Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research
Oct 12, 2017 04:01PM Gilead Sciences to Release Third Quarter 2017 Financial Results on Thursday, October 26, 2017
Oct 4, 2017 08:02AM Gilead Sciences (GILD) Presents Results From Phase 3 Study Evaluating Patients Who Switched to Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens
Oct 4, 2017 08:00AM Loncar Cancer Immunotherapy Index Announces Merger Replacements
Oct 4, 2017 08:00AM Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhi
Oct 4, 2017 05:43AM Gilead Sciences (GILD) Reports New License Agreement With the Medicines Patent Pool for Access to Bictegravir
Oct 4, 2017 03:01AM Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir
Oct 3, 2017 08:45AM Gilead Sciences Completes Acquisition of Kite Pharma, Inc.
Oct 3, 2017 08:01AM Gilead Sciences (GILD) Completes Tender Offer for Shares of Kite Pharma (KITE)
Oct 3, 2017 08:00AM Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.
Sep 27, 2017 04:31PM Gilead Sciences (GILD) Says COO Kevin Young to Retire
Sep 27, 2017 04:30PM Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire
Sep 26, 2017 08:31AM Gilead Sciences (GILD), Kite Pharma (KITE) Announce Expiration of HSR Waiting Period
Sep 26, 2017 08:30AM Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period
Sep 25, 2017 07:56AM Gilead (GILD) Announces China FDA Approval for Sovaldi for Treatment of Chronic Hepatitis C Virus Infection
Sep 25, 2017 07:55AM China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection
Sep 14, 2017 06:45PM Gilead Prices $3 Billion of Senior Unsecured Notes
Sep 5, 2017 04:01PM Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Monday, September 11
Sep 1, 2017 09:00AM Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6
Aug 28, 2017 07:01AM Gilead Sciences (GILD) Announces Agreement to Acquire Kite Pharma (KITE) for $11.9B
Aug 28, 2017 07:00AM Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
Aug 10, 2017 04:01PM Gilead Sciences (GILD) Reports FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Aug 10, 2017 04:01PM Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Aug 1, 2017 04:08PM Gilead Sciences (GILD) Announces FDA Approves Expanded Labeling for Epclusa
Aug 1, 2017 04:01PM U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
Jul 28, 2017 05:49AM Gilead Sciences (GILD) Gains Marketing Authorization for Vosevi in EU for HCV
Jul 28, 2017 05:46AM European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C
Jul 27, 2017 09:26AM Pre-Open Stock Movers 07/27: (CAPR) (SHOR) (FB) Higher; (CUR) (AZN) (CYH) Lower (more...)
Jul 26, 2017 04:02PM Gilead Sciences Announces Third Quarter 2017 Dividend
Jul 24, 2017 05:38AM Gilead Sciences (GILD) Reports Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Jul 24, 2017 05:06AM Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Jul 18, 2017 01:38PM Gilead Sciences (GILD) Vosevi Approved by FDA; Has Black Box Warning on Risk of HBV Reactivation
Jul 18, 2017 01:35PM U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus
Jul 13, 2017 06:58AM Gilead (GILD) Says EMA Validates MAA for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Jul 13, 2017 06:57AM European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Jul 12, 2017 05:00PM Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017
Jun 12, 2017 08:17AM Gilead Sciences (GILD) Submits NDA for Bictegravir, Emtricitabine and Tenofovir Alafenamide HIV Combo
Jun 12, 2017 08:15AM Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Jun 1, 2017 05:00PM Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15
May 30, 2017 05:00PM Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13
May 30, 2017 08:34AM Gilead Sciences (GILD) Combo of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies
May 30, 2017 08:30AM Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies
May 4, 2017 05:00PM Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18
May 2, 2017 04:02PM Gilead Sciences Announces Second Quarter 2017 Dividend
Apr 21, 2017 12:01PM Gilead Sciences (GILD) Says Scientific Presentations Showed Efficacy of Harvoni in Special Patient Populations With HCV Infection
Apr 21, 2017 12:00PM Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection
Apr 21, 2017 05:48AM Gilead Sciences (GILD) Reports POC Data for GS-0976 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017
Apr 21, 2017 04:30AM Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Apr 20, 2017 12:00PM Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread
View More Recent Stories View Older Stories